We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 30

China issues new rule on medical device advertisements
  • Sidley Austin LLP
  • China
  • June 5 2009

On May 13, the Ministry of Health (MOH), the State Administration of Industry and Commerce (SAIC) and the State Food and Drug Administration (SFDA) of China jointly issued an amended Rule for Review of Medical Device Advertisements (the Rule) and accompanying Standards for Review of Medical Device Advertisements (the Standards), both of which went into effect on May 20


China’s comprehensive health care reform plan: implications for pharmaceutical and device firms
  • Sidley Austin LLP
  • China
  • April 9 2009

On April 6, the State Council of China made public the Guideline on Further Reforming the Health Care System (the Guideline), and on the following day the Action Plan for Health Care System Reform: 2009 - 2011 (the Action Plan


SFDA’s working plan for the year of tiger
  • Sidley Austin LLP
  • China
  • February 16 2010

On January 19, 2010, officials from the State Food and Drug Administration (SFDA) and its local counterparts gathered together in Beijing to attend the 2010 National Conference on the Food and Drug Administration


China unveils draft regulations on labeling requirements for health foods
  • Sidley Austin LLP
  • China
  • June 7 2011

The State Food and Drug Administration ("SFDA") recently published an updated draft of the Rules on the Administration of Product Insert Sheets and Labels of Health Foods ("Draft Labeling Rules") for public comments


China promulgates new ADR reporting rules
  • Sidley Austin LLP
  • China
  • June 2 2011

On May 24, 2011, the Ministry of Health ("MOH") issued the revised Rules on Adverse Drug Reaction Reporting and Monitoring (the "Reporting Rules"), effective on July 1, 2011


MOH publishes new draft of Drug GSP regulation
  • Sidley Austin LLP
  • China
  • May 11 2012

On April 25, the Ministry of Health of China published a new draft of the Drug GSP for public comment, and key changes are:


China drug supply chain and GXP update
  • Sidley Austin LLP
  • China
  • January 4 2012

On December 23, 2011, the State Food and Drug Administration (SFDA) of China published the latest round of proposed revisions to the Drug Good Supply Practice Regulation (Draft GSP) for public comment by January 13, 2012


China issues five-year plan for pharmaceutical and medical device industries
  • Sidley Austin LLP
  • China
  • January 20 2012

On January 19, 2012, the Chinese Ministry of Industry & Information Technology issued the Twelfth Five-Year Plan (2011-2015) for the Development of Pharmaceutical and Medical Device Industries (the Plan


Updates on international pricing issues for pharmaceutical and biologic products
  • Sidley Austin LLP
  • China, European Union, France, Germany, United Kingdom, USA
  • May 18 2012

Sidley Austin LLP’s Global Life Sciences Team is pleased to provide you with this Global Pricing Newsletter, the first in a periodic series updating clients and friends of the firm on pricing issues around the world that may have an impact on pharmaceutical and biologic manufacturers’ legal and business strategies


China SFDA imposes new regulatory requirements on cross-border pharmaceutical contract manufacturing activities
  • Sidley Austin LLP
  • China
  • August 15 2011

On July 22, 2011, the China State Food and Drug Administration (“SFDA”) published a notice on strengthening its supervision over domestic contract manufacturing activities for foreign pharmaceutical manufacturers (the “Notice”), with an aim to prevent export counterfeiting